Hoenig Samuel M, Sarnaik Kunaal S, McCrindle Brian W, Welke Karl F, Mahboubi Rashed, Karamlou Tara
Case Western Reserve University School of Medicine, Cleveland, Ohio.
Labatt Family Heart Centre, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Ann Thorac Surg Short Rep. 2024 Oct 30;3(2):449-455. doi: 10.1016/j.atssr.2024.10.014. eCollection 2025 Jun.
Management options for critically cyanotic neonates with tetralogy of Fallot include primary repair, ductal or right ventricular outflow tract stents, and surgical shunts. However, rigorous comparisons between these strategies are precluded by small numbers, lack of equipoise, and center-specific bias.
A Markov model decision tree with Monte Carlo microsimulations was constructed to model 2-year outcomes for a hypothetical cohort of 10,000 cyanotic tetralogy of Fallot neonates eligible for all 3 strategies. Input transition state probabilities, utilities, and costs were derived from representative published reports. Outcomes were used to determine quality-adjusted life-years and costs after 50 model iterations. The incremental cost-effectiveness ratio was calculated to determine the preferred strategy. Sensitivity and threshold analysis varied probabilities of 40 factors to identify values at which the preferred strategy would switch.
From modeling, immediate mortality from index procedure favored staged approaches, but total mortality favored primary repair after approximately 6 months. Cumulative 2-year mortality from modeling was 8.1%, 11.6%, and 12.4% for primary repair, stenting, and shunting, respectively. Calculated incremental cost-effectiveness ratios identified primary repair as the preferred strategy, followed by stenting and then shunting. Sensitivity and threshold analysis identified total pathway cost to be the only determinant of altered strategy preference with respect to primary repair. For comparisons of staged approaches, several variables reflecting cost and outcomes were identified.
Our modeling suggests that primary repair may be superior to staging with stent or shunt for cyanotic neonates with tetralogy of Fallot, with improved 2-year morbidity, mortality, and cost utility.
法洛四联症严重发绀新生儿的治疗选择包括一期修复、导管或右心室流出道支架置入以及手术分流。然而,由于病例数量少、缺乏均衡性以及中心特异性偏倚,无法对这些策略进行严格比较。
构建一个带有蒙特卡洛微观模拟的马尔可夫模型决策树,以模拟10000名适合所有三种策略的法洛四联症发绀新生儿假想队列的2年结局。输入的转移状态概率、效用和成本来自代表性的已发表报告。在50次模型迭代后,使用结局来确定质量调整生命年和成本。计算增量成本效益比以确定首选策略。敏感性和阈值分析改变了40个因素的概率,以确定首选策略会发生转换的值。
通过建模,指数手术的即刻死亡率有利于分期治疗方法,但大约6个月后总死亡率有利于一期修复。建模得出的2年累积死亡率,一期修复、支架置入和分流分别为8.1%、11.6%和12.4%。计算得出的增量成本效益比确定一期修复为首选策略,其次是支架置入,然后是分流。敏感性和阈值分析确定总路径成本是与一期修复相比改变策略偏好的唯一决定因素。对于分期治疗方法的比较,确定了几个反映成本和结局的变量。
我们的建模表明,对于法洛四联症发绀新生儿,一期修复可能优于支架或分流分期治疗,可改善2年的发病率、死亡率和成本效用。